Parsons Capital Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Parsons Capital Management’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-750	Closed	-$96K	–	422
2021 Q2	$96K	Buy	+750	New	+$100K	0.01%	420

Other funds holding ACXP

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SFA

Semmax Financial Advisors Winston Salem, North Carolina $388M AUM 14.23% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Parsons Capital Management's ACXP Position: Q3 2021 in Review

Parsons Capital Management sold out of Acurx Pharmaceuticals (ACXP) in Q3 2021, closing a stake of 750 shares — an estimated $96K sold.

Parsons Capital Management first reported a position in ACXP in Q2 2021 and held it in 1 quarter. The position peaked at $96K in Q2 2021. 8 funds tracked by Wall St. Rank hold ACXP as of Q3 2021.

Parsons Capital Management reported no remaining Acurx Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Parsons Capital Management sold 750 Acurx Pharmaceuticals shares in Q3 2021, an estimated $96K.
Parsons Capital Management first reported a position in Acurx Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Parsons Capital Management's Acurx Pharmaceuticals position peaked at $96K in Q2 2021.
8 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2021.

Based on Parsons Capital Management's 13F filing for Q3 2021, filed 9 Nov 2021.